Accordingly, we show that camizestrant degraded ER to the same extent as fulvestrant in the ER+ Ishikawa endometrial cancer cell line, an in vitro model of ER agonism (Fig. 1E), with no evidence of PgR expression (as a marker of agonism), in contrast with AZD9496. The gene discussed is ESR1; the disease is endometrial cancer.